Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PPT versus DoxyPEP for STI control among cisgender men who have sex with men in Kenya
PACTR202407778358273Phase 4Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of doxycycline, cefixime and azithromycin in gonorrhea, Chlamydia trachomatis infection and syphilis (3 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Combined bacterial STI outcome. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
doxycyclinecefiximeazithromycin
03
Conditions
gonorrheaChlamydia trachomatis infectionsyphilis
Beyond the preview
Go deeper on PACTR202407778358273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202407778358273.